Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of recent studies regarding the use of FDA-approved and investigational agents for the treatment of chronic myeloid leukemia (CML)
- Discuss new insights into the etiology and prognostic indicators of CML
- Summarize new developments in the management of adverse events related to the treatment of CML
CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.